Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) announced management will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 10:00am ET. This virtual event will allow participants to gain insights into Protara's pipeline, including TARA-002, a cell-based therapy aimed at treating non-muscle invasive bladder cancer and lymphatic malformations.

The presentation will be available via webcast on the company's website, archived for 90 days for investor access.

News Market Reaction – TARA

+4.53%

+4.53% Session move

In the trading session that priced this news, TARA gained 4.53%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Ladenburg Thalmann Healthcare Conference being held in a virtual setting on Wednesday, July 14, 2021 at 10:00am ET.

A webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived on the Company’s website for 90 days following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com 
646-817-2836

FAQ

What is the date of Protara Therapeutics' presentation at the Ladenburg Thalmann Healthcare Conference?

Protara Therapeutics will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021.

Where can I watch the Protara Therapeutics presentation?

You can watch the Protara Therapeutics presentation by accessing the webcast on their website.

What is TARA-002?

TARA-002 is an investigational cell-based therapy developed by Protara Therapeutics for treating non-muscle invasive bladder cancer and lymphatic malformations.

How long will the Protara Therapeutics presentation be available online?

The presentation will be archived on Protara Therapeutics' website for 90 days following the event.